David J. Bearss - Concepedia

Author

David J. Bearss

Also Known As

B. Kaur, D BEARSS, D Bearss, D J Bearss, D. Bearss, D.J. Bearss, DJ Bearss, David Bearss, David J Bearss, David J. Bearss

257

Publications

9.7K

Citations

H-Index

Concepts

All Affiliations

University of Arizona Tolero Pharmaceuticals (United States)SuperGen (United States)Huntsman Cancer Institute University of Utah

About

David J. Bearss is an author at University of Arizona specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	2.8K
2	Natural Sciences	3	3	664
3	Biochemistry	3	3	308
4	Health Sciences	1	1	45
5	Public Health	1	1	33

David J. Bearss

Publications

8.4K

Citations

H-Index

Page 1

	Year	Citations
Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c- <i>MYC</i> transcription Adam Siddiqui-Jain, Cory L. Grand, David J. Bearss, Proceedings of the National Academy of Sciences	2002	2.2K
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance Lauren A. Byers, Lixia Diao, Jing Wang, Clinical Cancer Research	2012	1.1K
Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3 Wen‐Ming Yang, Carla Inouye, Yingying Zeng, Proceedings of the National Academy of Sciences	1996	541
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Haiyong Han, David J. Bearss, L. Walden Browne, PubMed Pancreatic CancerNormal Pancreas MrnaMedicineMicroarray Data AnalysisCdna Microarray	2002	379
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Cory L. Grand, Haiyong Han, Rubén M. Muñoz, PubMed Transcriptional RegulationCell RegulationMolecular RegulationCationic PorphyrinsMedicine	2002	370
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers Wen Zhou, Ye Yang, Jiliang Xia, Cancer Cell MedicineEfflux Drug PumpsPharmacologyCancer BiologyPoor Prognosis	2013	296
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors Daruka Mahadevan, Laurence Cooke, Christopher Riley, Oncogene Imatinib ResistanceChromatinOncologyGastrointestinal OncologyMedicine	2007	277
Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo Jeffrey A. Engelman, Richard J. Lee, Anthony N. Karnezis, Journal of Biological Chemistry	1998	211
High-Throughput Virtual Screening Identifies Novel <i>N</i>′-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors Venkataswamy Sorna, Emily R. Theisen, Bret J. Stephens, Journal of Medicinal Chemistry Drug TargetHit IdentificationHistone Lysine MethylationCompound LibraryReversible Lsd1 Inhibitors	2013	205
Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells Lisa S. Chen, Sanjeev Redkar, David J. Bearss, Blood	2009	198

Page 1